Background: Along with the hallmark symptoms of differences in communication and social behavior, many children with autism spectrum disorder (ASD) suffer from irritability. The U.S. Food and Drug Administration, or FDA, has approved two drugs - risperidone and aripiprasole (types of atypical antipsychotics) - to treat irritability associated with ASD in children. One common side effect of these drugs is significant weight gain.

What’s New: A new clinical trail has examined efficacy of another drug for reducing weight in children diagnosed with ASD and taking atypical antipsychotic drugs for irritability. Over the course of 16 weeks, the researchers conducted a randomized, controlled clinical trial in which they administered either a placebo or metformin - commonly used to treat diabetes - to 60 children between the ages of 6 and 17 with ASD who had experienced weight gain while taking an atypical antipsychotic drug. They found that the group taking metformin experienced significant weight loss, with reductions between 5 and 9 percent of their body mass index.

Why it’s important: This study suggests that the use of metformin could balance out the weight gain experienced by children taking atypical antipsychotics for irritability in ASD - helping them to have healthier outcomes. Future studies could determine whether this treatment is effective at maintaining weight loss, and whether it could prevent weight gain at the start of atypical antipsychotic drug treatment.

This study was published on August 24, 2016, in the scientific journal JAMA Psychiatry.

Autism Therapy

Source(s) :